Cargando…

Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series

Background. We report our experience with vinorelbine, a widely used chemotherapeutic, in unselected metastatic breast cancer patients treated in clinical routine. Patients and Methods. The data of all patients with metastatic breast cancer receiving vinorelbine with or without trastuzumab during a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stravodimou, Athina, Zaman, Khalil, Voutsadakis, Ioannis A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079952/ https://www.ncbi.nlm.nih.gov/pubmed/25006504 http://dx.doi.org/10.1155/2014/289836

Ejemplares similares

Pretreatment Thrombocytosis as a Prognostic Factor in Metastatic Breast Cancer
por: Stravodimou, Athina, et al.
Publicado: (2013)

Neurotrophic receptor tyrosine kinase family members in secretory and non-secretory breast carcinomas
por: Stravodimou, Athina, et al.
Publicado: (2022)

Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial
por: Chan, A, et al.
Publicado: (2006)

Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis of Our Series
por: Di Lauro, Vincenzo, et al.
Publicado: (2012)

Peroxisome Proliferator-Activated Receptor Gamma and Regulations by the Ubiquitin-Proteasome System in Pancreatic Cancer
por: Stravodimou, Athina, et al.
Publicado: (2012)

Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial
por: De Maio, Ermelinda, et al.
Publicado: (2007)

A Retrospective Analysis of Vinorelbine Chemotherapy for Patients With Previously Treated Soft-Tissue Sarcomas
por: Anderson, Sibyl E., et al.
Publicado: (2006)

Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2
por: Brain, E, et al.
Publicado: (2012)

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients
por: Cheng, Y C, et al.
Publicado: (2010)

Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial
por: Wang, Zijing, et al.
Publicado: (2021)

Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study
por: Bengala, C, et al.
Publicado: (2006)

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer
por: McLaughlin, Shannon, et al.
Publicado: (2023)

Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study
por: Serin, D, et al.
Publicado: (2005)

Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines
por: Berruti, A, et al.
Publicado: (2005)

All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial
por: Tubiana-Mathieu, N, et al.
Publicado: (2009)

Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group
por: Fløtten, Ø, et al.
Publicado: (2012)

Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
por: Sim, Sung Hoon, et al.
Publicado: (2019)

Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
por: Stemmler, H J, et al.
Publicado: (2011)

Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study
por: Cazzaniga, M. E., et al.
Publicado: (2014)

Oral vinorelbine in metastatic breast cancer
por: Conte, PF, et al.
Publicado: (2005)

A phase I trial of high-dose palliative radiotherapy plus concurrent weekly Vinorelbine and Cisplatin in patients with locally advanced and metastatic NSCLC
por: Michael, M, et al.
Publicado: (2005)

Phase II Study of Vinorelbine Plus Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes
por: Lee, Yu Rim, et al.
Publicado: (2011)

Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial
por: Wu, Shuo, et al.
Publicado: (2020)

Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study
por: Montemurro, Filippo, et al.
Publicado: (2008)

Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma
por: Sørensen, J B, et al.
Publicado: (2008)

Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis
por: Gebbia, Vittorio, et al.
Publicado: (2020)

Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure
por: Bonneterre, J, et al.
Publicado: (2002)

Mitomycin C and Vinorelbine for second-line chemotherapy in NSCLC – a phase II trial
por: Babiak, A, et al.
Publicado: (2007)

A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit
por: Brunetto, A T, et al.
Publicado: (2010)

C3 glomerulonephritis associated with monoclonal gammopathy: a retrospective case series study from a single institute in China
por: Zhang, Xin, et al.
Publicado: (2021)

Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series
por: Zagouri, F, et al.
Publicado: (2013)

Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer
por: Minuti, G, et al.
Publicado: (2012)

Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity
por: Helbekkmo, N, et al.
Publicado: (2007)

Trastuzumab-associated cardiac events in the Persephone trial
por: Earl, Helena M, et al.
Publicado: (2016)

Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer
por: Harder, J, et al.
Publicado: (2012)

Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring
por: Jones, A L, et al.
Publicado: (2009)

Epirubicin–vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial
por: Kerbrat, P, et al.
Publicado: (2007)

Outcome for Advanced or Metastatic Soft Tissue Sarcoma of Nonextremities Treated with Doxorubicin-Based Chemotherapy: A Retrospective Study from a Single Cancer Institution
por: Marshall, Shoko, et al.
Publicado: (2018)

Management of Cesarean Scar Pregnancy: A Single-Institution Retrospective Review
por: Giampaolino, P., et al.
Publicado: (2018)

Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison
por: Redana, Stefania, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_u4eh4l07qg2djk23k4rgggh2dr